Drug Discovery Services Market Report 2026

The drug discovery services market size has grown rapidly in recent years. It will grow from $20.52 billion in 2025 to $23.21 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to pharmaceutical r&d expansion, cost pressures on drug developers, cro service growth, target-based drug discovery, academic-industry collaborations.

The drug discovery services market size is expected to see rapid growth in the next few years. It will grow to $39.79 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to precision medicine pipelines, ai-driven discovery platforms, startup biotech funding, complex disease research, faster lead optimization needs. Major trends in the forecast period include increasing outsourcing of drug discovery activities, growing use of ai in target identification, expansion of early-stage discovery services, rising demand for biologics drug discovery, integration of in vitro and in vivo studies.

The rising prevalence of chronic diseases is expected to drive the growth of the drug discovery services market in the coming years. Chronic diseases are long-term health conditions that generally cannot be cured but can be managed effectively. Drug discovery services play a crucial role in identifying and developing new medications to treat these conditions. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older with at least one chronic condition is projected to increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the rising prevalence of chronic diseases is supporting the growth of the drug discovery services market.

Companies in the drug discovery services market are innovating with advanced technologies such as artificial intelligence (AI) and machine learning (ML) to improve the efficiency and accuracy of drug discovery processes. AI involves the development of computer systems capable of performing tasks that normally require human intelligence, while ML, a subset of AI, uses algorithms and statistical models to enable computers to learn from data and make predictions or decisions. For example, in February 2024, Eurofins Discovery, a France-based company offering services across multiple sectors including pharmaceuticals, launched DiscoveryAI SAFIRE (Suite of ADMET Predictions for In Silico Refinement and Evaluation). This platform leverages proprietary datasets, AI, and ML to enhance the drug discovery process by predicting the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of molecules. DiscoveryAI SAFIRE uses data from Eurofins Discovery’s extensive BioPrint database, curated over years of research, to accelerate the discovery of new pharmaceuticals.

In January 2023, Sygnature Discovery, a UK-based integrated drug discovery company, acquired SB Drug Discovery for an undisclosed amount. This acquisition provides a strategic advantage by expanding the capabilities and reach of both companies and aligns with Sygnature’s plan to continuously invest in its integrated drug discovery solutions. SB Drug Discovery is a UK-based company that supports novel drug development by providing critical services such as cell line generation, assay development, and compound screening.

Major companies operating in the drug discovery services market are Thermo Fisher Scientific Inc., Albany Molecular Research Inc., Charles River Laboratories International Inc., Laboratory Corporation of America Holdings, Domainex Ltd., GenScript Biotech Corporation, Pharmaceutical Product Development LLC, Advinus Therapeutics Pvt. Ltd., Jubilant Biosys Ltd., Evotec AG, Syngene International Ltd., Bayer AG, Merck KGaA, Ubiquigent Ltd., Eurofins Scientific SE, AppTec Laboratory Services Inc., GVK Biosciences Private Limited, Aurigene Discovery Technologies Limited, Viva Biotech Holdings, Pharmaron Beijing Co. Ltd., Selcia Limited, Concept Life Sciences Group Limited, BioDuro LLC, ChemPartner Corporation, Aptuit LLC, Sygnature Discovery Limited, Peak Proteins Ltd., SRI International, BioAscent Discovery Limited, Sai Life Sciences Limited, Promega Corporation, MedChemExpress LLC, Aragen Bioscience Inc., WuXi STA, BioNTech SE, Moderna Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals Inc., Amgen Inc., Bristol-Myers Squibb Company.

North America was the largest region in the drug discovery services market in 2025. The regions covered in the drug discovery services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the drug discovery services market by increasing costs of imported laboratory instruments, reagents, and screening technologies. CROs and biotech firms in North America and Europe are most affected due to high import dependency. These tariffs raise service costs by increasing capital investment and operational expenses for outsourced discovery activities, leading to higher contract pricing and longer project timelines for pharmaceutical clients. However, they also support domestic lab infrastructure development and regional sourcing strategies, encouraging local procurement of reagents, in-country instrument servicing, and expansion of regional CRO capabilities to reduce reliance on imported research inputs.

The drug discovery services market research report is one of a series of new reports that provides drug discovery services market statistics, including drug discovery services industry global market size, regional shares, competitors with a drug discovery services market share, detailed drug discovery services market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery services industry. This drug discovery services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug discovery services refer to the process of identifying potential new medicines, integrating multiple scientific disciplines such as biology, chemistry, and pharmacology. These services are provided across four stages: early drug discovery, pre-clinical phase, clinical phases, and regulatory approval.

The main types of drug discovery services include chemistry services and biology services. Chemistry services involve designing and synthesizing biologically active molecules to discover and optimize chemical compounds for drug development. These services utilize techniques such as high-performance liquid chromatography and high-field NMR to efficiently synthesize, analyze, and purify compound libraries. The processes include target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation, using drugs such as biologics and small molecules. End users of drug discovery services include pharmaceutical and biotechnology companies, academic institutes, and other organizations.

The drug discovery services market includes revenues earned by entities by providing pharmaceutical services, drug metabolism and pharmacokinetics (DMPK) services, biological services, and medicinal chemistry. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.